EGFR C797S

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma3
EGFR C797S	Erlotinib + OsimertinibCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID8080 A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. A set of osimertinib resistant tumours were treated with 25mg/kg osimertinib and 2… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic
EGFR C797S	Osimertinib	Predictive	D	Supports Resistance	4	submitted	EID8057 A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Lung Adenocarcinoma3

EGFR C797S

Erlotinib + OsimertinibCombination

Predictive

Supports Sensitivity Response

submitted

EID8080

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. A set of osimertinib resistant tumours were treated with 25mg/kg osimertinib and 2… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

civic

EGFR C797S

Osimertinib

Predictive

Supports Resistance

submitted

EID8057

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 ·

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376342	Uncertain significance	criteria provided, single submitter	1	EGFR-related lung cancer	germline	1	Aug 27, 2022	clinvar

Variation

Clinical significance

Review status

Stars

Conditions

Origin

Submitters

Last evaluated

Source

376342

Uncertain significance

criteria provided, single submitter

EGFR-related lung cancer

germline

Aug 27, 2022

clinvar

Lung Non-Small Cell Carcinoma3
EGFR C797S	Brigatinib + CetuximabCombination	Predictive	D	Supports Sensitivity Response	4	submitted	EID8028 Third generation EGFR inhibitor osimertinib can overcome the T790M resistance mutation on L858R or exon 19 del background. Drug screening of Ba/F3 cells expressing EGFR triple mutant (C797S/T790M/del1… (full text at CIViC) PMID 28287083 · Uchibori et al., 2017 · Open in CIViC	civic
EGFR C797S	Brigatinib + Cetuximab + PanitumumabCombination	Predictive	D	Supports Sensitivity Response	4	submitted	EID4837 Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance to Osimertinib. In the present study, we identif… (full text at CIViC) PMID 28287083 · Uchibori et al., 2017 · Open in CIViC	civic
EGFR C797S	Osimertinib	Predictive	B	Supports Resistance	3	accepted	EID964 An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expr… (full text at CIViC) PMID 25939061 · Thress et al., 2015 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma3

EGFR C797S

Brigatinib + CetuximabCombination

Predictive

Supports Sensitivity Response

submitted

EID8028

Third generation EGFR inhibitor osimertinib can overcome the T790M resistance mutation on L858R or exon 19 del background. Drug screening of Ba/F3 cells expressing EGFR triple mutant (C797S/T790M/del1… (full text at CIViC)

PMID 28287083 · Uchibori et al., 2017 · Open in CIViC

civic

EGFR C797S

Brigatinib + Cetuximab + PanitumumabCombination

Predictive

Supports Sensitivity Response

submitted

EID4837

Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance to Osimertinib. In the present study, we identif… (full text at CIViC)

PMID 28287083 · Uchibori et al., 2017 · Open in CIViC

civic

EGFR C797S

Osimertinib

Predictive

Supports Resistance

accepted

EID964

An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expr… (full text at CIViC)

PMID 25939061 · Thress et al., 2015 · Open in CIViC

civic

Malignant Lung Neoplasm1
EGFR T790M AND EGFR Exon 19 Deletion AND EGFR C797S	CH7233163	Predictive	D	Supports Sensitivity Response	3	submitted	EID13252 The novel tyrosine kinase inhibitor (TKI) CH7233163 has been reported to effectively overcome osimertinib resistance mediated by the EGFR Del19/T790M/C797S triple mutation. In vitro evaluation using e… (full text at CIViC) PMID 32943545 · Kashima et al., 2020 · Open in CIViC	civic

Malignant Lung Neoplasm1

EGFR T790M AND EGFR Exon 19 Deletion AND EGFR C797S

CH7233163

Predictive

Supports Sensitivity Response

submitted

EID13252

The novel tyrosine kinase inhibitor (TKI) CH7233163 has been reported to effectively overcome osimertinib resistance mediated by the EGFR Del19/T790M/C797S triple mutation. In vitro evaluation using e… (full text at CIViC)

PMID 32943545 · Kashima et al., 2020 · Open in CIViC

civic

Malignant Neoplasm2
EGFR C797S	Afatinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID8070 Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with afatinib suppressed EGFR phosphorylation of L858R+C797S, and caused complete inhibition… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic
EGFR C797S	Erlotinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID8076 Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with erlotinib suppressed EGFR phosphorylation of L858R+C797S mutants. Mice with EGFR L858R … (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic

Malignant Neoplasm2

EGFR C797S

Afatinib

Predictive

Supports Sensitivity Response

submitted

EID8070

Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with afatinib suppressed EGFR phosphorylation of L858R+C797S, and caused complete inhibition… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

civic

EGFR C797S

Erlotinib

Predictive

Supports Sensitivity Response

submitted

EID8076

Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with erlotinib suppressed EGFR phosphorylation of L858R+C797S mutants. Mice with EGFR L858R … (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

civic

Evidence by cancer (9 items)

Clinical significance (1)